<DOC>
	<DOCNO>NCT01532817</DOCNO>
	<brief_summary>The purpose pilot study collect preliminary clinical data relate safety preliminary clinical benefit non-invasive vagal nerve stimulation AlphaCore™ device relief acute bronchoconstriction due asthma . Up 30 subject meet inclusion/exclusion criterion consent participate study may enrol 5 investigational ( study ) sit . The study sit clinic setting capable treat potential complication bronchoconstriction , acute exacerbation asthma , emergency associate use investigational device .</brief_summary>
	<brief_title>Relief Acute Bronchoconstriction/Asthma Using Non-Invasive AlphaCore Device</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>INCLUSION CRITERIA : VISIT 1 1 . Is able give write Informed Consent . 2 . Is ages 18 65 year , male female . 3 . Has know history mild moderate asthma least 1 year define GINA Guidelines . 4 . Is use short act betaagonist relief/rescue asthma.. 5 . At Visit 1 , demonstrate current historical ( within 1 year ) FEV1 reversibility least 12 % ( 200ml ) great within 1530 minute follow administration 4 inhalation albuterol . EXCLUSION CRITERIA : VISIT 1 1 . Has history lung cancer , chronic obstructive pulmonary disease ( COPD ) , comorbidity associate irreversible narrowing airway . 2 . Has abscess infection lesion ( include lymphadenopathy ) AlphaCore™ treatment site . 3 . Has know suspect moderate severe atherosclerotic cardiovascular disease , carotid artery disease ( e.g . bruits history TIA CVA ) congestive heart failure ( CHF ) . 4 . Has suspect confirm sepsis . 5 . Has clinically significant irregular heart rate rhythm . 6 . Has experience recent clinically significant change blood pressure , uncontrolled high blood pressure , presently receive pressor maintain blood pressure . 7 . Is currently implanted electrical and/or neurostimulator device , include limited cardiac pacemaker , defibrillator , vagal neurostimulator , deep brain stimulator , spinal stimulator , bone growth stimulator , cochlear implant . 8 . Has history carotid endarterectomy vascular neck surgery right side . 9 . Has implant metal cervical spine hardware . 10 . Has recent repeat history syncope . 11 . Has recent repeat history seizure . 12 . Is pregnant nursing , childbearing year unwilling use accept form birth control . 13 . Is participate therapeutic clinical investigation participate clinical trial precede 30 day . 14 . Belongs vulnerable population condition ability provide inform consent , comply followup requirement , provide selfassessments compromise ( e.g. , homeless , developmentally disabled , prisoner ) . 15 . Is relative employee Investigator clinical study site . INCLUSION CRITERIA : VISIT 2 1 . No change occur patient 's health status relative original inclusion exclusion criterion patient continue eligible participation study . 2 . Either ( ) develop subjective symptom asthma ( wheeze , shortness breath , cough ) patient would normally selfmedicate short act beta agonist , and/or ( ii ) document drop 20 % screen PEF score record patient diary . 3 . At Visit 2 , FEV1 low screen FEV1 previously measure visit 1 PEF low screen previously measure Visit 1 . EXCLUSION CRITERIA : VISIT 2 1 . The patient selfadministered shortacting beta agonist within 6 hour prior onset asthma symptom . 2 . The patient induce asthma exacerbation withhold pretreatment medication use exerciseinduced bronchoconstriction ( EIB ) . 3 . Has sign symptom asthma instability Visit 2 : Lung Function : FEV1 &lt; 50 % predict . Signs symptoms extreme respiratory distress rest . Rapid deterioration respiratory status ( sudden change respiratory rate , decrease oxygen saturation , change consciousness , etc . ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>